AC
Aaron Cowen
Suvretta Capital · Investor
1Y performance ⓘ
+44%
AUM (13F)
$3.8B
# of Holdings
87
3Y performance ⓘ
+95%
vs S&P 500 ⓘ
+31%
Updated
Mar 31
Aaron Cowen's Suvretta Capital holds 87 U.S.-equity positions worth $3.8B (SEC 13F, Q1 2026). Top positions: Arcutis Biotherapeutics, Inc. Common Stock 7.4%, Veradermics, Incorporated 6.7%, State Str Spdr S&p 500 Etf T 5.8%. 13F-replication return is +95% over 3 years (+31 pts vs the S&P 500) — a replicated, non-audited figure.
Holdings
| Stock | % of portfolio | Shares | Value | Latest activity | Avg buy price | Current price | Date |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics, Inc. Common Stock | 7.4% | 12.3M | $290M | ▲ 3.0% (+363K) | $9.34 | $26.86 (+188%) | 2026-03-31 |
| MANE Veradermics, Incorporated | 6.7% | 4.2M | $263M | NEW (+4.2M) | $63.15 | $105.00 (+66%) | 2026-03-31 |
| SPY PUT State Str Spdr S&p 500 Etf T | 5.8% | 350K | $228M | ▼ 56% PUT (−450K) | — | — | 2026-03-31 |
| PVLA Palvella Therapeutics, Inc. Common Stock | 3.7% | 1.2M | $144M | ▲ 29% (+261K) | $47.87 | $139.04 (+190%) | 2026-03-31 |
| APLSUSD Apellis Pharmaceuticals Inc | 3.6% | 3.5M | $142M | ▼ 15% (−621K) | $31.91 | — (+26%) | 2026-03-31 |
| LEGN Legend Biotech Corp | 3.5% | 7.6M | $137M | ▲ 15% (+972K) | $26.77 | $18.55 (−31%) | 2026-03-31 |
| BNTC Benitec Biopharma Inc. Common Stock | 3.1% | 11.5M | $123M | — | $9.76 | $11.71 (+20%) | 2026-03-31 |
| CAPR Capricor Therapeutics Inc | 3.0% | 3.8M | $116M | ▲ 114% (+2.0M) | $29.68 | $3.85 (−87%) | 2026-03-31 |
| IMTX Immatics N.V. Ordinary Shares | 2.8% | 11.2M | $110M | — | $6.08 | $8.66 (+42%) | 2026-03-31 |
| RCUS Arcus Biosciences, Inc. | 2.8% | 5.0M | $109M | ▼ 3.0% (−158K) | $13.70 | $28.19 (+106%) | 2026-03-31 |
| EYPT EyePoint, Inc. Common Stock | 2.7% | 8.3M | $107M | ▲ 6.0% (+469K) | $9.43 | $12.25 (+30%) | 2026-03-31 |
| AVBP ArriVent BioPharma, Inc. Common Stock | 2.6% | 4.4M | $102M | ▲ 7.2% (+295K) | $20.42 | $29.82 (+46%) | 2026-03-31 |
| TSM Taiwan Semiconductor Manufac | 2.6% | 299K | $101M | ▲ 10% (+27K) | $128.36 | $404.25 (+215%) | 2026-03-31 |
| NVDA NVIDIA CORP | 2.6% | 575K | $100M | ▲ 8.2% (+44K) | $136.83 | $200.75 (+47%) | 2026-03-31 |
| META Meta Platforms, Inc. Class A Common Stock | 2.5% | 170K | $97M | — | $250.39 | $556.71 (+122%) | 2026-03-31 |
| GE GE Aerospace | 2.2% | 310K | $88M | — | $147.92 | $360.07 (+143%) | 2026-03-31 |
| BHVN Biohaven Ltd. | 2.2% | 10.3M | $87M | — | $17.57 | $13.50 (−23%) | 2026-03-31 |
| SYY Sysco Corporation | 2.1% | 1.2M | $83M | ▲ 7.0% (+75K) | $72.50 | $85.24 (+18%) | 2026-03-31 |
| MGM MGM RESORTS INTERNATIONAL | 2.0% | 2.2M | $80M | ▲ 80% (+957K) | $36.72 | $44.57 (+21%) | 2026-03-31 |
| CMPX Compass Therapeutics, Inc. Common Stock | 1.9% | 14.3M | $76M | ▲ 0.9% (+125K) | $3.08 | $1.91 (−38%) | 2026-03-31 |
| HD Home Depot, Inc. | 1.9% | 222K | $73M | ▼ 8.0% (−19K) | $373.16 | $331.96 (−11%) | 2026-03-31 |
| KURA Kura Oncology, Inc. | 1.8% | 8.6M | $70M | — | $10.36 | $9.01 (−13%) | 2026-03-31 |
| GLUE Monte Rosa Therapeutics, Inc. Common Stock | 1.8% | 4.2M | $70M | ▲ 26% (+867K) | $6.67 | $16.52 (+148%) | 2026-03-31 |
| BAC Bank of America Corporation | 1.6% | 1.3M | $63M | ▼ 15% (−222K) | $47.01 | $61.95 (+32%) | 2026-03-31 |
| ERAS Erasca, Inc. Common Stock | 1.4% | 3.4M | $56M | ▼ 76% (−11.1M) | $2.20 | $18.15 (+727%) | 2026-03-31 |
| COF Capital One Financial | 1.4% | 302K | $55M | ▲ 76% (+130K) | $153.47 | $209.01 (+36%) | 2026-03-31 |
| ZURA Zura Bio Limited Class A Ordinary Shares | 1.4% | 9.1M | $54M | ▲ 63% (+3.5M) | $6.00 | $5.43 (−9%) | 2026-03-31 |
| AMZN Amazon.Com Inc | 1.4% | 254K | $53M | ▼ 37% (−152K) | $168.59 | $271.58 (+61%) | 2026-03-31 |
| AMD Advanced Micro Devices | 1.3% | 257K | $52M | ▼ 34% (−132K) | $102.99 | $476.15 (+362%) | 2026-03-31 |
| FULC Fulcrum Therapeutics, Inc. Common Stock | 1.3% | 6.6M | $50M | — | $5.29 | $3.58 (−32%) | 2026-03-31 |
| VMC Vulcan Materials Company(Holding Company) | 1.3% | 182K | $49M | NEW (+182K) | $272.30 | $268.57 (−1%) | 2026-03-31 |
| FERG Ferguson Enterprises Inc. | 1.3% | 212K | $49M | ▲ 33% (+53K) | $216.79 | $234.33 (+8%) | 2026-03-31 |
| APO Apollo Global Management, Inc. | 1.1% | 388K | $43M | ▼ 29% (−155K) | $111.69 | $125.59 (+12%) | 2026-03-31 |
| MLYS Mineralys Therapeutics, Inc. Common Stock | 1.1% | 1.5M | $42M | — | $19.80 | $25.52 (+29%) | 2026-03-31 |
| CRNX Crinetics Pharmaceuticals, Inc. | 1.0% | 1.0M | $38M | NEW (+1.0M) | $36.32 | $83.52 (+130%) | 2026-03-31 |
| CTNM Contineum Therapeutics, Inc. Class A Common Stock | 0.9% | 2.8M | $37M | — | $15.17 | $15.49 (+2%) | 2026-03-31 |
| USFD US Foods Holding Corp. | 0.9% | 396K | $37M | NEW (+396K) | $92.21 | $100.59 (+9%) | 2026-03-31 |
| PFGC Performance Food Group Company | 0.8% | 387K | $33M | NEW (+387K) | $85.66 | $114.39 (+34%) | 2026-03-31 |
| REPL Replimune Group, Inc. | 0.8% | 4.2M | $32M | ▲ 11615% (+4.2M) | $7.67 | $11.20 (+46%) | 2026-03-31 |
| MSOS Advisorshares Tr | 0.8% | 9.0M | $32M | ▲ 4.3% (+377K) | $4.73 | $4.23 (−11%) | 2026-03-31 |
| AURA Aura Biosciences, Inc. Common Stock | 0.8% | 4.4M | $29M | — | $6.01 | $7.01 (+17%) | 2026-03-31 |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | 0.7% | 101K | $27M | ▼ 9.6% (−11K) | $375.39 | $414.40 (+10%) | 2026-03-31 |
| PROK ProKidney Corp. Class A Ordinary Shares | 0.6% | 12.3M | $22M | — | $2.42 | $1.54 (−36%) | 2026-03-31 |
| LTH Life Time Group Holdings, Inc. | 0.3% | 510K | $14M | NEW (+510K) | $26.94 | $45.10 (+67%) | 2026-03-31 |
| WHWK Whitehawk Therapeutics, Inc. Common Stock | 0.3% | 3.7M | $13M | — | $1.78 | $3.85 (+116%) | 2026-03-31 |
| ABEO Abeona Therapeutics Inc. Common Stock | 0.3% | 2.7M | $12M | — | $4.24 | $6.42 (+51%) | 2026-03-31 |
| WING Wingstop Inc | 0.2% | 60K | $9M | NEW (+60K) | $167.07 | $129.49 (−22%) | 2026-03-31 |
| MOLN Molecular Partners Ag | 0.2% | 2.2M | $9M | — | $4.98 | — (−20%) | 2026-03-31 |
| BSX Boston Scientific Corp. | 0.2% | 124K | $8M | ▼ 65% (−230K) | $77.98 | $46.73 (−40%) | 2026-03-31 |
| LXEO Lexeo Therapeutics, Inc. Common Stock | 0.2% | 1.2M | $7M | — | $9.93 | $4.13 (−58%) | 2026-03-31 |
Showing top 50 of 87 holdings by value.
FAQ ▾
What are Aaron Cowen's largest holdings?
As of the latest 13F: Arcutis Biotherapeutics, Inc. Common Stock 7.4%, Veradermics, Incorporated 6.7%, State Str Spdr S&p 500 Etf T 5.8%, Palvella Therapeutics, Inc. Common Stock 3.7%, Apellis Pharmaceuticals Inc 3.6%.
How big is Suvretta Capital's 13F portfolio?
$3.8B across 87 disclosed U.S.-equity positions.
What is Aaron Cowen's 3-year performance?
+95% (13F-replication, price return), +31 pts vs the S&P 500. Not an audited fund return.
Where does this data come from?
U.S. SEC Form 13F-HR institutional holdings filings.
Sourced from SEC Form 13F-HR filings · Not investment advice ▾
Data as of 2026-03-31 · Methodology
13F-replication (price return, filing-date based) — not an audited fund return.
Published by WealthFile · Not investment advice.
Latest activity = change vs. the prior 13F. Avg buy price = est. entry over the trailing 3 years (gain = vs. latest price). Returns are 13F-replication, not audited fund returns. Sourced from SEC 13F filings.